{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-027257","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2022-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.924175+00:00","generated_at":"2026-06-24T06:34:51.054321+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"TransMedics Q2 revenue up 151% to $20.5M, raises 2022 guidance to $67M-$75M","bullets":["Net revenue $20.5M in Q2 2022 vs $8.2M a year ago (+151%); gross margin improved to 70% from 68%.","Net loss of $11.5M vs $10.7M in Q2 2021; operating expenses rose to $24.1M from $15.5M.","Entered $60M five-year loan with CIBC, replacing $35M OrbiMed facility; netted $23M cash.","Full-year 2022 revenue guidance raised to $67M-$75M (prior $59M-$65M), representing 121%-148% YoY growth.","National OCS Program drove 84% of US revenue; integrated OCS Heart DCD into NOP."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-027257","json":"https://secwatch.observer/filing/0001564590-22-027257.json","markdown":"https://secwatch.observer/filing/0001564590-22-027257.md","text":"https://secwatch.observer/filing/0001564590-22-027257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000156459022027257/0001564590-22-027257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000156459022027257/tmdx-8k_20220801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:34:51.054321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}